$4.080
+0.324 (+7.94%)收盤時
PRLD 資訊
PRLD 事件
Prelude Therapeutics Announces Clinical Trial Collaboration with Eli Lilly
Prelude Therapeutics (PRLD) announced a clinical trial collaboration and supply agreement with Eli Lilly (LLY) for supply of its CDK4/6 kinase inhibitor, abemaciclib and its oral estrogen receptor antagonist, imlunestrant. The agreement supports the evaluation of Prelude's clinical development candidate PRT13722, an oral KAT6A selective degrader, in combinations with abemaciclib and imlunestrant in a Phase 1 trial in patients with HR+/HER2- breast cancer. The FDA recently cleared the company to proceed with the Phase 1 study under its investigational new drug, or IND, application for PRT13722. The company expects to begin enrolling patients in the fourth quarter of 2026 beginning with monotherapy dose escalation and rapidly advancing to various combination cohorts. Prelude maintains full global development and commercial rights to PRT13722 as a wholly owned program.
Prelude Therapeutics Receives FDA Approval for Phase 1 Study of PRT13722
Prelude Therapeutics announced that the FDA cleared the company to proceed with a Phase 1 study under its Investigational New Drug Application for PRT13722, an oral KAT6A selective degrader being developed for the treatment of patients with HR+/HER2- breast cancer. The company expects to begin enrolling patients in the fourth quarter of 2026.
Prelude CEO Highlights Strong Execution in First Half of 2026
"The first six months of 2026 were highlighted by steady and strong execution across our organization," stated Kris Vaddi, Chief Executive Officer of Prelude. "We've made considerable progress advancing our three core programs. Notably, we are well positioned to initiate, in the fourth quarter, the first clinical trial of our highly differentiated, selective KAT6A degrader, PRT13722 in HR+ breast cancer. Enrollment in our phase 1 study of PRT12396, our mutant-selective JAK2V617F inhibitor, continues, and we are also making excellent progress toward advancing the lead development candidates from our mCALR degrader antibody conjugate program."
Prelude Therapeutics Shares Rise 20% to $4.67
Shares of Prelude Therapeutics (PRLD) after moving higher after Incyte (INCY) in its Q2 earnings release that after a review of available data, it has discontinued further development of INCB160058 to prioritize its next-generation JAK2V617F-targeted pipeline. On November 4, 2025, Prelude announced an exclusive option agreement with Incyte focused on Prelude's mutant selective JAK2V617F JH2 inhibitor program in development for patients with myeloproliferative neoplasms. Per the agreement, Incyte has an exclusive option to acquire the JAK2V617F program in exchange for an upfront payment and a strategic equity investment in Prelude, plus potential downstream milestones and royalties. Shares of Prelude Therapeutics are up 20% to $4.67 in morning trading. Incyte is up 6% to $125.48 following its earnings report.
Prelude CEO States Focused Execution of Strategic Priorities
"Through this first quarter of 2026, our company has continued to demonstrate focused execution of the strategic priorities we set forth late last year." stated Kris Vaddi, Chief Executive Officer of Prelude. "Since the beginning of this year, we've advanced PRT12396 into first-in-human studies, presented promising preclinical data from our highly selective KAT6A degrader development candidate, continued to progress towards a development candidate from our mCALR program and importantly, extended our cash runway into the second quarter of 2028."
相關文章
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
- AppLovin Q3 2026 Deep Dive: Beaten-Down S&P Dog Meets Axon Next-Gen Beat-and-Raise—and a $3.2B BuybaAppLovin Q3 2026: $2.185B rev (+55%), EPS $4.30 vs ~$4.03–4.04 Street, Adj EBITDA $1.842B (84%). Beat own guide $100M; Q4 $2.365–2.395B; auth +$3.2B; AH +22–24%.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。